Translational NeuroImaging of the CNS: Novel Pathways to Drug Development

被引:14
|
作者
Fox, Gerard B. [1 ]
Chin, Chih-Liang [1 ]
Luo, Feng [1 ]
Day, Mark [1 ]
Cox, Bryan F. [1 ]
机构
[1] Abbott Labs, Global Pharmaceut Res & Dev, Abbott Pk, IL 60064 USA
关键词
POSITRON-EMISSION-TOMOGRAPHY; TRANSGENIC MOUSE MODEL; ALZHEIMERS-DISEASE; PHARMACOLOGICAL MRI; BRAIN ACTIVATION; WHITE-MATTER; HIPPOCAMPAL ATROPHY; GLUCOSE-UTILIZATION; COGNITIVE DECLINE; AMYLOID PLAQUES;
D O I
10.1124/mi.9.6.6
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Scientists engaged in drug discovery and development face many critical issues along the road to identifying the best drug candidates to bring forward for testing in patients. In neuroscience, these challenges can involve particularly demanding questions regarding target engagement, the predict ability of endpoints in animal models, new disease model validation, CNS penetration, and the identification of pharmacodynamic markers. For neurological conditions such as Alzheimer's disease, clinical trials of novel drugs that may modify the course of disease, rather than targeting specific symptoms, add extra layers of complexity. Major studies designed to track the course of a disease increasingly depend on noninvasive, translational imaging. In this brief review, we highlight examples of the new wave of neuroimaging studies that engender useful biomarkers of disease for translational research.
引用
收藏
页码:302 / 313
页数:12
相关论文
共 50 条
  • [41] The current development of CNS drug research
    Wegener, Gregers
    Rujescu, Dan
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2013, 16 (07): : 1687 - 1693
  • [42] CNS Drug Development - Lost in Translation?
    Talevi, A.
    Bellera, C. L.
    Di Ianni, M.
    Gantner, M.
    Bruno-Blanch, L. E.
    Castro, E. A.
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2012, 12 (10) : 959 - 970
  • [43] Phosphodiesterases in the CNS: targets for drug development
    Frank S. Menniti
    W. Stephen Faraci
    Christopher J. Schmidt
    Nature Reviews Drug Discovery, 2006, 5 : 660 - 670
  • [44] Phosphodiesterases in the CNS: targets for drug development
    Menniti, Frank S.
    Faraci, W. Stephen
    Schmidt, Christopher J.
    NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (08) : 660 - 670
  • [45] Imaging Biomarkers in CNS Drug Development
    Tauscher, J.
    Schwarz, A.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 : 34 - 35
  • [46] The utility of biomarkers in CNS drug development
    Palmer, Alan M.
    DRUG DISCOVERY TODAY, 2014, 19 (03) : 201 - 203
  • [47] TARGETING LIN28 REGULATED PATHWAYS IN NOVEL THERAPEUTICS DEVELOPMENT FOR CNS ATYPICAL TERATOID/RHABDOID TUMOR (CNS ATRT)
    Kannappan, Sunand
    Gupta, Mehul
    Zhang, Chunfen
    Hofmann, Bradley
    Chi, Susan
    Hanson, Derek
    Narendran, Aru
    NEURO-ONCOLOGY, 2019, 21 : 66 - 66
  • [48] TRANSLATIONAL STRATEGIES FOR RESPIRATORY DRUG DEVELOPMENT
    Ward, Christine K.
    INFLAMMATION RESEARCH, 2010, 59 : S277 - S277
  • [49] Translational Bioinformatics Approaches to Drug Development
    Readhead, Ben
    Dudley, Joel
    ADVANCES IN WOUND CARE, 2013, 2 (09) : 470 - 489
  • [50] Functional neuroimaging: proof of concept for drug development
    Bye, A
    Williams, SCR
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S10 - S11